Skip to main content

Table 3 Outcome distribution among the three echinocandin groups

From: Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication

  Anidulafungin Caspofungin Micafungin
Number of patients, n 1700 4431 6547
Patient-days in observation period
 Total person-days 26,449 85,020 102,267
 Distribution person-days across patients (all patients)
  Median [IQR] 9.0 (2.0, 20.0) 12.0 (5.0, 23.0) 10.0 (4.0, 20.0)
  Mean ± SD [Range] 15.6 ± 23.3 (1–309) 19.2 ± 31.7 (1–938) 15.6 ± 20.0 (1–350)
Severe hepatotoxicity eventsa
 Patients with severe hepatotoxicity events, n (% of all patients) 633 (37.2) 993 (22.4) 1522 (23.2)
 Grade of first severe hepatotoxicity event in the observation period, n (% of all patients)
  Grade 3 504 (29.6) 870 (19.6) 1289 (19.7)
  Grade 4 129 (7.6) 123 (2.8) 233 (3.6)
  Grade 5b
Status at hospital discharge, n (% of patients with events)
 Recovered 198 (31.3) 316 (31.8) 491 (32.3)
 Not recovered 423 (66.8) 643 (64.8) 990 (65.0)
 Unknown 12 (1.9) 34 (3.4) 41 (2.7)
  1. Abbreviations: IQR inter-quartile range, SD standard deviation
  2. aA severe hepatotoxic event was defined as the first hepatotoxicity of Grade ≥ 3 in the observation period. Hepatotoxicity grade was classified according to the modified Clinical Islet Transplantation study–Terminology Criteria for Adverse Events in trials of adult pancreatic islet transplantation (CIT-TCAE) Version 5.0 [13]
  3. bGrade 5 events cannot be the first event experienced by the patient because Grade 5 events (deaths) must be preceded, by definition, by a liver function test of Grade 4